Fresenius admits strong finish to 2013 needed to strike target
This article was originally published in Clinica
Executive Summary
Fresenius Medical Care will need a “very strong fourth quarter” to hit its guidance for 2013, admitted CEO Rice Powell as the firm reported third-quarter results. The company is anticipating full-year revenues of over $14.6bn, representing 6% year-on-year growth, and net income of $1.1-1.15bn, which is now expected to come in at the low end of this range.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.